EC approves Takeda's Livtencity

The European Commission (EC) has granted approval for the marketing authorization application for Livtencity (maribavir) that was submitted by Japan’s largest drugmaker Takeda (TYO: 4502).

The drug is cleared for the treatment of cytomegalovirus (CMV) infection and/or diseases that are refractory (with or without resistance) to one or more prior therapies, including ganciclovir, valganciclovir, cidofovir or foscarnet, in adult patients who have undergone a hematopoietic stem cell transplant (HSCT) or solid organ transplant (SOT).

Livtencity is the first and only oral treatment that inhibits CMV-specific UL97 protein kinase and its natural substrates, said Takeda.